Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL4687 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL3119262 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL8192290 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL5835621 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL5544656 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL8532996 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL6374631 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL27504027 | 0.98 | GRM5 (0.48) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL5196221 | 0.91 | GRM5 (0.57) | GRM5CA2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225161-A1 | GABA and L-glutamic acid analogs for antiseizure treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-04 | — | — | US | claimed |
| EP-0925292-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING SUBSTITUTED CHROMANOL DERIVATIVES | PFIZER (US) | 2003-09-10 | — | — | EP | claimed |
| US-6180238-B1 | PARTICULARLY SUITABLE FOR USE IN INK JET PRINTING PROCESSES. | XEROX CORPORATION | 2001-01-30 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673784-B1 | Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds | XEROX CORP (US) | 1999-10-27 | — | — | EP | claimed |
| US-5729266-A | Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salt, morpholine, thiazole, thiazolidine, thiadiazole and phenothiazine compounds | XEROX CORPORATION (US) | 1998-03-17 | — | — | US | claimed |
| EP-0641330-A4 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT. | UNIV NORTHWESTERN (US) | 1997-05-28 | — | — | EP | claimed |
| EP-0672687-B1 | Process for producing amino-functional cyclodextrin derivatives | CONSORTIUM ELEKTROCHEM IND (DE) | 1997-03-19 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5536826-A | OXAZOLIDINONE OR DERIVATIVE | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1996-07-16 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673784-A2 | Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| EP-0672687-A1 | Process for producing amino-functional cyclodextrin derivatives | Consortium für elektrochemische Industrie GmbH (DE) | 1995-09-20 | — | — | EP | claimed |
| EP-0641330-A1 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT | NORTHWESTERN UNIVERSITY (US) | 1995-03-08 | — | — | EP | claimed |
| EP-0378657-B1 | OXAZOLIDINONE PENETRATION ENHANCING COMPOUNDS | RAJADHYAKSHA VITHAL J (US) | 1994-02-02 | — | — | EP | claimed |
| WO-1993023383-A1 | GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT | NORTHWESTERN UNIVERSITY (US) | 1993-11-25 | — | — | WO | claimed |
| US-4960771-A | TRANSDERMAL DELIVERY OF THERAPEUTIC AGENTS; DRUGS, SUNSCREENS, INSECT REPELLENTS, COSMETICS | LVMH MOET HENNESSY LOUIS VUITTON, INC. | 1990-10-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225161-A1 | GABA and L-glutamic acid analogs for antiseizure treatment | GABRB1, GABRE, GABRB2 | GRM5 50/4885CA2 319/4885SLC6A2 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.